For further details see:
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2021 Results - Earnings Call TranscriptFor further details see:
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2021 Results - Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
Market:
Allogene Therapeutics Inc. Website:
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expect...
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday. Shares of DLocal Limited (NASDAQ:...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...